KNOPP BIOSCIENCES is a drug discovery and development company focused on delivering breakthrough treatments for unmet medical needs through innovation, experience and partnership. Our clinical and preclinical programs focus on novel mechanisms of mitochondrial energetics and our lead compound, dexpramipexole, is currently in Phase 3 clinical development for amyotrophic lateral sclerosis. Additional programs include dexpramipexole combination therapy for Parkinson’s disease and the discovery of ion channel modulators for pain and epilepsy.